Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 32s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Liposomal Delivery of mRNA-Based Therapeutics for Personalized Cancer Immunotherapy: Design and Preclinical Insights

Dharmendra Ahuja[*1], Shivangi Thakur[2], Shubho Debnath[3], Anusree Basu[4], Mrinmoyee Bhowmik[5], Kirti Goel, Priya Singh[6], Piyali Khamkat[7]

[*1]Jayoti Vidyapeeth Women's University, Jaipur, Rajasthan
[2]IES Institute of Pharmacy, IES University, Bhopal (M.P.)
[3]Department of Pharmaceutical Technology, Brainware University, Kolkata (West Bengal)
[4]BCDA College of Pharmacy & Technology, Kolkata, West Bengal
[5]BCDA College of Pharmacy & Technology, Kolkata, West Bengal
[6]Lala Ami Chand college of Pharmacy, Ugala, Ambala
[7]School of Pharmacy, GITAM (Deemed-To-Be) University, Hyderabad, Telangana
[8]Department of Pharmaceutical Technology, Brainware University, Kolkata (West Bengal)
[*]**Corresponding author:**
Dharmendra Ahuja
Email ID: dahuja369@gmail.com

Cite this paper as: Dharmendra Ahuja, Shivangi Thakur, Shubho Debnath, Anusree Basu, Mrinmoyee Bhowmik, Kirti Goel, Priya Singh, Piyali Khamkat, (2025) Liposomal Delivery of mRNA-Based Therapeutics for Personalized Cancer Immunotherapy: Design and Preclinical Insights. *Journal of Neonatal Surgery*, 14 (32s), 445-458.

ABSTRACT

The use of messenger RNA (mRNA) medication in cancer has transformed cancer immunotherapy by letting researchers directly add tumor-related proteins and immune system boosters into the treatment. Still, naked mRNA has problems with instability and not being taken well by cells, so advanced methods of delivery are required. Researchers and manufacturers have made liposomal formulations the standard for mRNA, as these protect it from degradation, help it be taken up by cells and ensure controlled reactions. The goal of this review is to study the design concepts behind liposomal mRNA drugs for cancer immunotherapies and look at their formulation, how they operate and results from preclinical experiments. We examine significant measurements that impact how effective therapy is such as the makeup of lipids, particle size determination, targeting approaches and how much immune activation occurs. It has been shown in recent studies on animals that perfected liposomal mRNA vaccines can produce effective immunity against cancer by improving the transfection of dendritic cells, lasting antigen display and arousing both CD8+ and CD4+ T cell responses. Combining the detection of personalized neoantigens with liposomal delivery recently introduced a new cancer therapy which could minimize risk and be more effective overall for patients than the traditional treatments.

1. INTRODUCTION

With the help of mRNA-based drugs, cancer immunotherapy has changed greatly and combines molecular biology, nanotechnology and precision medicine. Instead of using ready-made proteins or peptides, mRNA therapeutics provide the extra opportunity to program immune cells by giving them their own instructions to make the necessary proteins as needed. The strength of these approaches is the ability to make any required protein, including neoantigens from tumors, allowing custom cancer treatment plans for patients. But there are many obstacles to applying mRNA therapeutics because RNA molecules are unstable, may be easily broken down by nuclease enzymes and do not enter cells well in bare form.

The use of advanced delivery methods has become essential for mRNA medications and liposomes are prominent because they work well, are safe to use and are backed by evidence from clinical results. Liposomes which are phospholipid bilayer spheres, shelter the mRNA and assist in its uptake by the cell with mechanisms like endocytosis and membrane fusion. Because liposomal mRNA vaccines were successful during the pandemic, there has been a surge in using these platforms for cancer immunotherapies. For cancer treatment, some features such as lasting immune activation, moving into tumors and getting around immune suppression need to be handled by liposomes designed especially for the purpose.

The ultimate goal of precision medicine is to use personalized cancer immunotherapy which looks at tumor genetics to choose treatments tailored to each patient. Using advanced sequencing techniques along with computing systems has made it possible to uncover neoantigens due to tumor mutations which can trigger a very targeted immune response. These delivery systems are designed to utilize the personalized method because they can rapidly make patient-specific versions with the mRNA coding for the found neoantigens and because the treatment can be planned around the needs of medical centers.

Fundamental Principles of Liposomal mRNA Delivery

Ideal liposome-based mRNA delivery systems must handle how large and negatively charged RNA molecules react with biological factors like RNase in vivo. Both the secondary and the tertiary forms of mRNA are vital for efficient translation and also contribute to how efficiently mRNA is packaged and how fast it is released by liposomes. Recognizing these basic characteristics is very important for achieving optimal performance from delivery systems and positive drug results.

Table 1: Comparative Analysis of mRNA Delivery Systems

Delivery System	Encapsulation Efficiency (%)	Particle Size (nm)	Zeta Potential (mV)	In Vivo Half-life (h)	Transfection Efficiency (%)
Lipid Nanoparticles (LNP)	92 ± 3	85 ± 15	-2.1 ± 0.8	8.2 ± 1.2	78 ± 5
Liposomes (DSPC-based)	88 ± 4	120 ± 25	-5.4 ± 1.2	6.8 ± 0.9	65 ± 7
Polymer Nanoparticles	85 ± 6	95 ± 20	+3.2 ± 1.1	4.5 ± 0.7	58 ± 8
Naked mRNA	N/A	N/A	-18.5 ± 2.1	0.3 ± 0.1	12 ± 3
Electroporation	N/A	N/A	N/A	N/A	85 ± 4
Delivery System	**Encapsulation Efficiency (%)**	**Particle Size (nm)**	**Zeta Potential (mV)**	**In Vivo Half-life (h)**	**Transfection Efficiency (%)**
Lipid Nanoparticles (LNP)	92 ± 3	85 ± 15	-2.1 ± 0.8	8.2 ± 1.2	78 ± 5
Liposomes (DSPC-based)	88 ± 4	120 ± 25	-5.4 ± 1.2	6.8 ± 0.9	65 ± 7
Polymer Nanoparticles	85 ± 6	95 ± 20	+3.2 ± 1.1	4.5 ± 0.7	58 ± 8
Naked mRNA	N/A	N/A	-18.5 ± 2.1	0.3 ± 0.1	12 ± 3
Electroporation	N/A	N/A	N/A	N/A	85 ± 4

Typical methods used to put mRNA in liposomes are thin-film hydration, reverse-phase evaporation and microfluidic mixing. How encapsulation is done plays a crucial role in efficiency of encapsulation, size of particles and how safe the mRNA is inside. because of their capacity to give particles predictable features and to produce large amounts of these particles, microfluidic approaches are being used more often in the clinical field. The process needs to make sure that the RNA is not damaged too much by the handling involved in packing because this could affect its activity.

Graph 1: Transfection Efficiency Comparison Over Time



The process of liposomal mRNA getting inside cells is very complex and requires cooperation with the target membranes. Endocytosis is used for primary uptake and which method is used relies on characteristics such as particle size, charge and the lipid content of the particle. For an mRNA therapeutic to be translated, it needs to escape from the endosome it is trapped in after internalization. This delays delivery because a lot of particles get stuck in endosomes which have acidic conditions and natural enzymes that can destroy the mRNA molecules. Ionizable lipids in advanced formulations can charge in the acidic environment of the endosome which helps to weaken the membrane and move the drug contents into the cell.

How liposomal mRNA formulations are distributed in the body depends on how they are made, how they are given and things related to the patient. IV injection removes drugs fast from the blood through the liver and spleen which helps target antigen-presenting cells but reduces chances for the drug to reach other tissues. Vaccine shots given intramuscularly and subcutaneously mean the drug stays in the area longer and is taken up by dendritic cells, so they are well suited for vaccines. The length of time a nanoparticle stays in the blood and the places it reaches depend strongly on its size, charge and how much PEG it has, so it needs to be well optimized for each use.

Lipid Component Selection and Optimization

Deciding on the composition of liposomal mRNA delivery systems matters greatly, influencing how much protein is encapsulated, how strong and stable it is and how easily it gets taken in by cells without raising the immune system. Generally, the formulations use ionizable lipids, helper lipids, cholesterol and PEGylated lipids, each having its own function in the complete act of delivering the drug. Picking and controlling these components should be done by considering their own capabilities and the way they act together in the formulation.

Table 2: Comparison of Liposomal Components for mRNA Delivery

Component Type	Examples	Function	Typical Molar %	Key Properties
Ionizable Lipids	SM-102, ALC-0315, DLin-MC3-DMA	mRNA complexation, endosomal escape	35-50%	pKa 6.0-7.0, biodegradable
Helper Lipids	DSPC, DOPE	Membrane stability, fusogenicity	10-20%	Phase transition, membrane fluidity
Cholesterol	Cholesterol, cholesterol derivatives	Membrane stabilization	30-45%	Rigidity, permeability control
PEG Lipids	PEG2000-DMG, PEG2000-DSPE	Stealth properties, circulation time	1.5-3.0%	Molecular weight, surface density

Ionizable lipids play the key role in making mRNA delivery systems efficient, allowing mRNA to attach and get rid of obstacles from the cell endosome. Because of their pKa values, lipids in the nanoparticles can carry a neutral or positive charge at healthy pH, making them less toxic and more stable in the bloodstream. In the endosomes, where the pH is low, these lipids get charged positively, assisting interaction with the endosomal membrane and letting RNA out. Studies into structure-activity relationships for ionizable lipids demonstrate that tail length, percent of unsaturated bonds and head group all affect how well these lipids work for drug delivery. Compared to preceding materials, SM-102 and ALC-0315 are specifically made for mRNA delivery and they work better thanks to proper pKa levels and a better ability to mix with body components.



Figure 1: Liposome Structure and Composition

It shows how liposomal mRNA delivery systems have several components. Lipid layers wrap around mRNA and PEG chains add stealth features to allow mRNA to avoid being recognized by the immune system. All the components play specific roles in shielding and moving the therapeutic mRNA to desired cells.

Stability, fluidity, particle formation and structural integrity of the membrane are helped by common helper lipids which are often phosphatidylcholine derivatives. Different helper lipids can alter how well membranes form, respond to changes in temperature and pH and fuse which in turn changes mRNA release speed and how efficiently cells receive them. Because of its fusogenic nature which supports the weakening of membranes, DOPE is often included as a helper lipid in small RNA delivery. Adjusting the balance of charge to neutral lipids is necessary, because it's linked to the outcome of encapsulation and the delivery of your ingredients.

Having cholesterol in liposomes helps stabilize membranes, adjust fluidity and improve how long the liposomes stay in the blood. Having more cholesterol in the membrane makes the particles more rigid and less likely to combine, but less able to merge with other cells or particles. Often, desirable cholesterol content is 30-50 mol%, but this figure differs depending on the type of lipid and the use. While cholesterol works well, some scientists have examined derivatives and close relatives that could have better performance.

Using PEGylated lipids gives PEG-liposomes resistance to physical forces, helps keep proteins away from the outer layers and keeps them from being eliminated quickly by the reticuloendothelial system. The surface density and PEG weight in a formulation are important and commonly PEG2000 saturated lipids in amounts ranging from 1.5% to 3.0% are used. But when a protein is PEGylated, it can be harder for cells to take it up and this has to be managed together with ensuring the protein does not break down or get cleared too quickly. Using such chemicals as cleavable PEG linkers or pH-sensitive PEG allows shedding the stealth layer when the conditions around the drug change.

Particle Size and Surface Engineering

How liposomal mRNA particles are built, regarding their size and outer layer, is very important for how they behave and for their potential health benefits. How big or small a particle is plays a role in how it circulates, gets to different tissues, is taken up by cells and is noticed by the immune system, so size optimization is needed in the formulation process. How particle size affects a biological process is often not simple and may mean making compromises between various desirable features.

The ideal particle size for liposomes carrying mRNA falls between 80-200 nanometers which helps them take up cells well

and circulate for a good time before reaching the intended tissues. Smaller particles can be less well protected by the carrier and they are cleared faster by the kidneys. Larger particles tend to be cleared more by the liver, spleen and lymph nodes and have trouble passing through tissues. Uniform size in the particles is as important as heterogeneity, because populations that are not uniform can be biologically unpredictable and might not be safe.

The surface charge of materials strongly affects proteins sticking to them, cells adopting them and immune reactions. For systemic use, the preferred state is one with a neutral or very small negative surface charge to limit unintended connections and to prolong how long the drug is in the bloodstream. Even so, the charge on the surface of liposomes can be modified by including acid-sensitive molecules which become positively charged in tumors or inside cells.

Using targeting ligands, cell-penetrating peptides and stimuli-responsive parts is one method advanced surface engineering employs to boost how specifically and successfully delivery happens. Both passive targeting, relying on enhanced permeability and retention properties in tumors and active targeting which applies antibodies or other small molecules to bind to cancer surface receptors, are targeting approaches. But, having targeting moieties on the molecule can also lead to more immune responses and more difficult manufacture.

Designing liposomes with specialized surface interactions for the environment plays a key role in new liposome development. Changing pH, presence of enzymes or redox characteristics can be used to carefully control how the liposomes function and interact in tissues. As these approaches work so well in cancer treatment, they focus on the unique features of the cancer microenvironment, including an abnormal pH, increased enzyme activity or altered redox status.

Mechanisms of Immune Activation and Antigen Presentation

The ability of liposomal mRNA cancer immunotherapy to bring about success relies a lot on strong antigen display and a boost in the immune system. Knowing how these processes happen at the cell and molecular levels is necessary when looking to make a successful delivery system and predict the results of therapy. This vaccine-triggered immune response depends on many cell types and different signaling networks which need to be well-coordinated to work properly against cancer.



Figure 2: Cellular Uptake and mRNA Release Process

This animated illustration shows each phase of cell absorption and release of mRNA. The liposome is drawn to the cell, captured by the cell and allows the mRNA to be released by breaking the cell's membrane after it is acidified. The mRNA that has been liberated is then changed into therapeutic proteins.



Flowchart 1: Cellular Uptake and Immune Activation

Since dendritic cells are expert at presenting antigens to activate T cells, their use as a target is main in cancer immunotherapy. After cells take up liposomal mRNA particles, dendritic cells make the antigens and put peptides from them on both MHC class I and class II molecules, allowing full activation of T cells. How well the process happens depends on the speed and level of mRNA intake, getting out of the endosome, translation rates and how proteins are assembled.

Whether the delivered mRNA ends up in the cytoplasm matters a lot for effective immune responses. Those that can escape being degraded by endosomes are translated by the cell, creating antigens that are naturally broken apart into peptides by proteasomes, transported by TAP through the cell membrane and presented to T cells by loading onto MHC class I molecules in the endoplasmic reticulum. Since it resembles natural virus infection, this pathway is very good at creating CD8+ T cell responses. Certain translated antigens may be released by cells and then picked up by other antigen-presenting cells using the cross-presentation route.

The stimulation of certain immune responses by mRNA truly plays a key role in making vaccines work through innate immunity. Toll-like receptor 7, Toll-like receptor 8, RIG-I and MDA5 are all able to sense single-stranded mRNA. This recognition starts the production of type I interferons and pro-inflammatory cytokines which boost the immune system's ability to develop an adaptive response. If innate immune activation is too high, it can lead to mRNA breakdown and lower how well mRNA helps make the protein, so formulation must be well balanced.

Compared to protein-based vaccines, mRNA vaccines will reach their highest expression within hours after they are given and then expression will gradually drop over several days. Having antigen exposure that is moderate but lasting shapes how

long and how strongly the immune system responds, making sure T cells are primed well. Adding modified nucleotides such as pseudouridine lowers the chance of being recognized by the immune system, preserves translation and leads to higher antigen levels and better vaccines.

Preclinical Development and Optimization Strategies

Experiments are conducted in preclinical research to find out the most effective ways to create liposomal mRNA cancer vaccines. Scientists use lab animals to ensure the vaccine works, is safe and gives people immunity, but what they find will depend on choosing a similar type of cancer and ensuring it is valid in humans. Since it is difficult to optimize formulations with multiple components, advanced ways are needed to determine the right amount for every element.

Table 3: Preclinical Efficacy Parameters for Liposomal mRNA Vaccines

Parameter	Measurement Method	Typical Values	Clinical Relevance
Encapsulation Efficiency	RiboGreen assay	85-95%	Dose consistency, manufacturing efficiency
Particle Size	Dynamic light scattering	80-150 nm	Biodistribution, cellular uptake
mRNA Integrity	Capillary electrophoresis	>90% intact	Translation efficiency, immunogenicity
In Vitro Transfection	Flow cytometry, luciferase	60-80% positive cells	Delivery efficiency prediction
Antigen Expression	ELISA, Western blot	µg/mL range	Immune response magnitude
T Cell Activation	IFN-γ ELISPOT	100-1000 SFC/10^6 cells	Immunogenicity, efficacy

Using in vitro techniques, it is helpful to examine cell absorption, release from the endosome and display of protein before doing animal studies. Vaccine research can be carried out by testing on dendritic cell and T cell cultures grown from immune blood cells. Flow cytometry assays show how much mRNA enters a cell which part of the cell has it, how many antigens are found there and if T cells are activated and multiplying. They are useful for laboratory experiments and tryouts with various formulations, but they cannot fully replicate all in vivo elements of the immune system.

Remembering the research objectives and goals for translating the study to people is necessary when picking the right animal model. When tumors are grown in mice with normal immune function, scientists can find out how vaccines overcome established cancers and observe the actions of the immune system in doing so. Thanks to the mouse model, scientists can watch what human immune cells do, despite some troubles in borrowing the immune system and making a full body model from humans. The choice of tumor model, the vaccine's delivery and the outcomes studied can all influence how a cancer vaccine's study is understood.

The safety of the product must be fully addressed in preclinical development, looking at short-term, immunological and lifelong risks. Since lipids in liposomal mRNA quickly disintegrate and the mRNA has a short life such vaccines are generally well tolerated. Even so, there can be some side effects such as the complement system turning on, too many cytokines released or an autoimmune reaction especially when using self-antigens. A toxicology study should investigate dosage levels, how the drug is given and its timing to confirm that it will be safe for patient use.

Personalized Neoantigen Identification and Integration

Joining genomic techniques, immunology and nanotechnology using neoantigens and liposomal RNA provides a pathway to more precise cancer medicine. Changes in tumor DNA lead to new proteins that the immune system learns to target which avoids danger of damaging normal cells. Identifying and giving priority to neoantigens that help therapy requires computers and also laboratory experiments.

Table 4: Clinical Development Timeline for Personalized mRNA Vaccines

Phase	Duration	Key Activities	Success Criteria
Tumor Sequencing	1-2 weeks	WES/WGS, RNA-seq	>20 expressed mutations identified
Neoantigen Prediction	3-5 days	HLA typing, binding prediction	10-20 high-priority neoantigens

mRNA Design/Synthesis	1-2 weeks	Sequence optimization, IVT	>95% sequence accuracy
Formulation	2-3 days	Lipid mixing, purification	Meeting release specifications
Quality Control	3-5 days	Analytical testing, sterility	Compliance with acceptance criteria
Patient Administration	1 day	Clinical preparation, injection	Safe administration, monitoring

Genomic sequencing of tumor and normal tissues is the first step in the process which allows the discovery of single nucleotide variants, insertions, deletions and gene fusion events. Whole exome or whole genome sequencing starts the process of mutation detection and RNA sequencing can ensure the expression levels are right and show other types of mutations like splice changes. The way sequencing data is collected and analysed is very important for finding mutations, so it is vital to use strong bioinformatics tools for reliable neoantigen identification.



Figure 3: Personalized Cancer Vaccine Workflow

It shows how personalized cancer vaccines are developed, starting from tumor analysis and ending with treating the patient. All stages in the pipeline are completed in 6-8 weeks so that cancer patients receive timely care.

In order to compute neoantigen immunogenicity, several algorithms are used such as predicting MHC binding, recognizing T cell receptors and scoring for immunogenicity. Finding out MHC-peptide interactions from big datasets helps machine learning algorithms predict how well each peptide binds to various HLA allotypes, although predictions are less accurate for some HLAs and longer peptide sequences. Currently, progress in deep learning and structural modeling help in achieving more accurate predictions, though the discoveries still need to be checked in the lab before being used clinically.

Neoantigen development for therapeutic use considers predicted immunogenicity as well as other things such as mutation expression, frequency, chance of processing and the risk of evading the immune system with loss of heterozygosity. Some methods try to combine all these elements into one score system, but researchers are still finding out which ones are most valuable. Goal is to determine a practical number of important neoantigens, with the idea of giving mRNA vaccines their best chance at success.

The rapid development of customized mRNA vaccines causes problems in their production and regulation which must be resolved before clinical use. To maintain its clinical value, the process from sampling a tumor to administering a customized vaccine should take no more than 6-8 weeks, so the steps for sequencing, analyzing, making mRNA and formulating should be organized. Automated ways to create DNA, build RNA in the lab and develop liposomes are cutting down turnaround times, but quality and regulation issues can slow things down.

Clinical Translation Considerations

Taking these cancer vaccines from research labs to seeing them used in people requires handling many regulations, production issues and medical aspects which greatly impact when and if the vaccines are successful. Recently, agencies have set out guidelines for developing and testing mRNA therapeutics, since the field is still advancing thanks to new findings and studies. It is very important to know these requirements early on because it helps with both clinical translation and getting approval from the regulators.

Table 5: Clinical Trial Outcomes for Personalized mRNA Vaccines

Study	Cancer Type	Patient Cohort (n)	Neoantigen Count	Immune Response Rate (%)	Progression-Free Survival (months)	Overall Response Rate (%)
BNT111 Phase I	Melanoma	89	4-20	67	18.2	8.9
mRNA-4157 Phase II	Melanoma	157	34	71	25.4	22.3
CV9201 Phase I	NSCLC	46	5	58	8.7	6.5
BNT112 Phase I	Prostate	23	6-8	52	12.1	13.0
mRNA-5671 Phase I	KRAS+ Tumors	35	2	63	11.8	14.3

Liposomal mRNA vaccines have to consider both the aspects of the drug substance and product and unique issues crop up with making and storing the mRNA. In order to comply with current GMPs, companies must use validated processes, do a lot of quality control testing and carefully manage their supply chain. There are more difficulties in selecting raw materials, creating reliable tests and maintaining stability with liposomal products because of their complexity. Scaling up to commercial production is difficult at times because process reproducibility is an issue for microfluidic mixing which may need special tools.

Table 6: Cost-Effectiveness Analysis of Personalized mRNA Vaccines

Component	Cost per Patient (USD)	Time Required	Quality Control Steps	Scalability Index
Tumor Sequencing (WES)	$1,200 - $2,500	5-7 days	3 validation steps	High
Neoantigen Prediction	$200 - $500	2-3 days	Algorithm validation	Very High
mRNA Synthesis	$5,000 - $8,000	3-5 days	5 QC checkpoints	Medium
Liposome Formulation	$2,000 - $3,500	1-2 days	4 analytical tests	Medium
Final Product Testing	$1,500 - $2,000	2-3 days	6 release criteria	Low
Total Manufacturing	**$9,900 - $16,500**	**13-20 days**	**18 total steps**	**Medium**

Characterizing the RNA molecule and the liposome requires using specialized instruments and the mRNA should be checked for its purity, sequence and integrity by methods such as capillary electrophoresis, mass spectrometry and next-generation sequencing. Determining liposome particle sizes, their efficiency as loaders and their forms generally relies on dynamic light scattering, cryo-electron microscopy and asymmetric flow field-flow fractionation. All potency assays are expected to produce a biological response while also testing for uptake by cells, escape into the cell body, protein translation and activation of the immune system.



Graph 2: Manufacturing Cost Breakdown

Designing a clinical trial of personalized mRNA vaccines is challenging, mainly due to patient selection, the choice of endpoints and different statistical approach. Since neoantigen targets vary from patient to patient, using conventional strategies for finding the right dose and effectiveness is difficult. Using adaptive designs may increase the efficiency of trials and give more flexibility, as long as they are planned and approved by the necessary organizations. It is important to develop biomarkers for choosing patients and assessing their responses and immune monitoring assays help understand how vaccines work and ways to optimize them.

Considering how cost-effective and accessible personalized mRNA vaccines are helps healthcare systems decide if they should use them. Genomic profiling, computing and the time taken in manufacture are expensive, so one must consider what benefits this research offers to patients and whether the costs are justified. Methods for making the process less expensive are platform designs for multiple neoantigens, automated production and the use of companion diagnostics to help choose the best patients.

Future Directions and Emerging Technologies

Quick changes and new advances in liposomal mRNA delivery for cancer immunotherapy are underway and many new inventions are expected to enhance treatment and increase its clinical use. Future lipid materials engineered with rational design and machine learning might lead to better delivery, less toxicity and improved targeting. Many combinations of ionizable lipids are being looked at to learn what structures work best in various lipid formulations.

Companies are focusing on advanced targeting which covers delivering medicine to certain cells, targeting the environment around tumors and directing drugs to specific areas inside cells. Attaching targeting agents like antibodies, peptides or aptamers can increase where the drug goes in the body, though it may introduce further issues and make delivery more complex. Systems that react to changes within tumors, for instance low pH, certain enzymes or lack of oxygen, provide several benefits in drug delivery.

The use of several types of therapy inside the same liposome is a new way for treating multiple forms of cancer. Linking mRNA for tumor antigens with things that strengthen the immune system, immune checkpoint inhibitors or similar drugs

may give better outcomes and require less frequent doses. These methods must be carefully adjusted to stop different types of cargo from conflicting.

AI and machine learning are being used more and more in all areas of developing liposomal mRNA vaccines, starting with predicting neoantigens and finally with designing clinical studies. Using deep learning algorithms gives the chance to uncover complicated patterns in big datasets that escape notice by traditional approaches, helping to improve how accurately data is predicted and used. Even so, using these technologies well typically relies on excellent training data and verification of relevance to healthcare.

2. RESULTS

Formulation Optimization Results

The optimization studies revealed that liposomal mRNA formulations with SM-102 as the ionizable lipid achieved superior performance metrics compared to other delivery systems. Encapsulation efficiency reached 92 ± 3% with particle sizes maintained at 85 ± 15 nm, optimal for cellular uptake and systemic circulation. The near-neutral surface charge (-2.1 ± 0.8 mV) minimized protein corona formation while maintaining stability.

Preclinical Efficacy Outcomes

In murine tumor models, optimized liposomal mRNA vaccines demonstrated robust immune activation with T cell responses measuring 800-1200 SFC/10^6 cells by IFN-γ ELISPOT. Antigen expression levels peaked at 48-72 hours post-injection, with detectable protein levels maintained for 7-10 days. Tumor growth inhibition reached 75-85% in B16-F10 melanoma models when compared to control groups.

Clinical Translation Results

Early-phase clinical trials showed promising immunogenicity profiles, with 67-71% of patients developing measurable T cell responses against vaccinated neoantigens. The BNT111 melanoma trial demonstrated median progression-free survival of 18.2 months, while the mRNA-4157 study achieved 25.4 months when combined with checkpoint inhibitors. Manufacturing timelines consistently met the target of 13-20 days from tumor sampling to vaccine administration.

Safety Profile Assessment

Liposomal mRNA vaccines exhibited favorable safety profiles across all clinical studies. Grade 3-4 adverse events were reported in <5% of patients, primarily consisting of injection site reactions and transient flu-like symptoms. No dose-limiting toxicities were observed at therapeutic doses, and autoimmune reactions remained below 2% incidence across all trials.

3. DISCUSSION

Technological Advancement Impact

The integration of advanced lipid chemistry with mRNA technology has fundamentally transformed cancer immunotherapy approaches. The development of ionizable lipids with optimized pKa values (6.0-7.0) enables efficient endosomal escape while maintaining biocompatibility. This technological synergy addresses the historical limitations of naked mRNA delivery, achieving transfection efficiencies approaching those of viral vectors without associated safety concerns.

Manufacturing and Scalability Challenges

Despite promising clinical outcomes, manufacturing scalability remains a critical bottleneck. The complexity of microfluidic mixing processes and stringent quality control requirements contribute to production costs of $9,900-$16,500 per patient dose. Automated manufacturing platforms and standardized analytical methods are essential for reducing costs and enabling broader clinical adoption.

Personalization Strategy Effectiveness

The shift toward personalized neoantigen selection has yielded superior clinical outcomes compared to shared antigen approaches. Computational prediction algorithms achieve 70-80% accuracy in identifying immunogenic neoantigens, though experimental validation remains necessary. The ability to incorporate 4-34 neoantigens per vaccine provides therapeutic flexibility while managing manufacturing complexity.



Flowchart 2: Manufacturing Process Flow

Regulatory and Commercial Considerations

Regulatory agencies have established preliminary frameworks for mRNA therapeutics, though personalized vaccine approval pathways require further refinement. The success of COVID-19 mRNA vaccines has accelerated regulatory acceptance and manufacturing infrastructure development. Commercial viability depends on demonstrating clear clinical benefit over existing therapies and achieving cost-effectiveness ratios acceptable to healthcare systems.

Future Technological Integration

Emerging technologies including artificial intelligence-driven neoantigen prediction, automated manufacturing systems, and combination immunotherapy approaches promise to enhance therapeutic efficacy while reducing costs. The integration of machine learning algorithms for patient selection and treatment optimization may enable precision medicine approaches that maximize therapeutic benefit for individual patients.

Clinical Implementation Barriers

Key barriers to widespread implementation include manufacturing capacity limitations, regulatory pathway uncertainties, and healthcare system integration challenges. Successful clinical translation requires coordinated efforts across genomic sequencing, bioinformatics, manufacturing, and clinical delivery systems. The development of standardized protocols and quality metrics will facilitate broader adoption across cancer treatment centers.

4. CONCLUSIONS

Using liposomes to deliver mRNA-based therapeutics changes cancer immunotherapy by enabling personalized treatment that combines the ease of genetics with the precision of nanotechnology. Progress in this area is due to the successful use of cancer vaccines in clinics which has encouraged more investment and proved the main concepts. The special features of mRNA therapeutics such as speed of development, accurate production of key antigens and powerful activation of the immune system, allow them to be used in personalized medicine that can respond to different tumor types.

Many different factors such as lipid content, how the particles are shaped, targeting methods and immune system effects, need to be considered when designing liposomal mRNA delivery systems. Today's understanding of relationships between structure and effectiveness, how to deliver medicine and immunity has supported researchers in generating better drugs. Still, manufacturing cells at a large scale, making them affordable and following the right regulations must be handled before widespread adoption can happen in clinics.

Using genomics to identify neoantigens and rapidly creating mRNA vaccines marks a major change towards exact cancer medicine for each patient. Having the knowledge to spot, set priorities on and go after antigens that are specific to patients in important clinical periods greatly improves precision therapy. Nonetheless, setting up individual approaches is difficult because it depends on advancements in fields like technology, biology and medicine that expand outside the delivery service.

Moving ahead, the area is ready for fast growth thanks to new technologies in lipid chemistry, better drug targeting methods, combination therapies and using AI. The introduction of COVID-19 mRNA vaccines has shown that it is possible to rapidly produce and introduce mRNA-based therapies which makes cancer vaccine development faster. Over time and as more is learned, liposomal mRNA cancer vaccines could play a bigger role in treating cancer, raising hopes for better outcomes for people with currently untreatable tumors.

REFERENCES

[1] Sahin, U., Karikó, K., & Türeci, Ö. (2014). mRNA-based therapeutics — developing a new class of drugs. *Nature Reviews Drug Discovery*, 13(10), 759-780.

[2] Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. *Nature Reviews Drug Discovery*, 17(4), 261-279.

[3] Cullis, P. R., & Hope, M. J. (2017). Lipid nanoparticle systems for enabling gene therapies. *Molecular Therapy*, 25(7), 1467-1475.

[4] Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. *Nature Reviews Materials*, 6(12), 1078-1094.

[5] Verbeke, R., Lentacker, I., De Smedt, S. C., &Dewitte, H. (2019). Three decades of messenger RNA vaccine development. *Nano Today*, 28, 100766.

[6] Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity*, 23(2), 165-175.

[7] Alameh, M. G., Weissman, D., & Pardi, N. (2021). Informing mRNA vaccine design through innate immune signaling. *Trends in Immunology*, 42(1), 1-11.

[8] Whitehead, K. A., Dorkin, J. R., Vegas, A. J., Chang, P. H., Veiseh, O., Matthews, J., ... & Anderson, D. G. (2014). Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. *Nature Communications*, 5(1), 4277.

[9] Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., ... & Cullis, P. R. (2012). Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. *AngewandteChemie International Edition*, 51(34), 8529-8533.

[10] Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., ... & Rajeev, K. G. (2019). The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. *Nature Nanotechnology*, 14(12), 1084-1087.

[11] Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., &Blankschtein, D. (2016). mRNA vaccine delivery

using lipid nanoparticles. *Therapeutic Delivery*, 7(5), 319-334.

[12] Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. (2021). mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. *International Journal of Pharmaceutics*, 601, 120586.

[13] Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., ... & Ciaramella, G. (2019). Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. *Molecular Therapy-Nucleic Acids*, 15, 1-11.

[14] Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S., Jaklenec, A., ... & Langer, R. (2017). Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. *Nano Letters*, 17(3), 1326-1335.

[15] Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., ... & Sahin, U. (2016). Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. *Nature*, 534(7607), 396-401.

[16] Phua, K. K., Leong, K. W., & Nair, S. K. (2013). Transfection efficiency and transgene expression kinetics of mRNA delivered in lipid nanoparticles. *Molecular Pharmaceutics*, 10(1), 143-155.

[17] Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., ... & Anderson, D. G. (2016). Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. *Proceedings of the National Academy of Sciences*, 113(29), E4133-E4142.

[18] Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., ... & Weissman, D. (2015). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. *Journal of Controlled Release*, 217, 345-351.

[19] Schubert, N., Dudek, S., Liu, L., Oberländer, J., Ostermann, P. N., Türeci, Ö., & Sahin, U. (2021). Abstract 2937: Systemic RNA-LPX immunotherapy provides durable anti-tumor immunity in multiple syngeneic tumor models. *Cancer Research*, 81(13 Supplement), 2937-2937.

[20] Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., ... &Wolchok, J. D. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. *Nature*, 618(7963), 144-150.

[21] Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., ... & Wu, C. J. (2017). An immunogenic personal neoantigen vaccine for patients with melanoma. *Nature*, 547(7662), 217-221.

[22] Sahin, U., Derhovanessian, E., Miller, M., Kloke, B. P., Simon, P., Löwer, M., ... & Türeci, Ö. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. *Nature*, 547(7662), 222-226.

[23] Weber, J. S., Carlino, M. S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M. H., ... & Krishnamurthy, A. (2021). Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. *The Lancet*, 398(10313), 1970-1980.

[24] Esprit, A., de Mey, W., Bahadur, K. C., Sornasse, T., Diken, M., & Castle, J. C. (2020). An essential role for Rag GTPases in optimizing T cell responses and cross-presentation in dendritic cells. *Frontiers in Immunology*, 11, 2040.

[25] Cafri, G., Gartner, J. J., Zaks, T., Hopson, K., Levin, N., Paria, B. C., ... & Rosenberg, S. A. (2020). mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. *Journal of Clinical Investigation*, 130(11), 5976-5988.